Search

Your search keyword '"Banfield, C"' showing total 235 results
Start Over Author "Banfield, C"
235 results on '"Banfield, C"'

1. OP09 Oral ritlecitinib and brepocitinib in patients with moderate to severe active Crohn’s Disease: Data from the PIZZICATO umbrella study

Author

Vermeire, S, primary, Allegretti, J R, additional, Kim, H J, additional, Long, M D, additional, Leszczyszyn, J, additional, Schreiber, S, additional, Mross, M R, additional, Kierkus, J, additional, Peeva, E, additional, Vincent, M S, additional, Shojaee, N, additional, Banfield, C, additional, Banerjee, A, additional, Gale, J D, additional, and Hung, K E, additional

Published
2024
Full Text
View/download PDF

3. Physico-chemical properties of maize (Zea mays L.) mucilage differ with the collection system and corresponding root type and developmental stage of the plant

Author

Werner, L.M., Knott, M., Diehl, D., Ahmed, M.A., Banfield, C., Dippold, M., Vetterlein, Doris, Wimmer, M.A., Werner, L.M., Knott, M., Diehl, D., Ahmed, M.A., Banfield, C., Dippold, M., Vetterlein, Doris, and Wimmer, M.A.

Abstract

Purpose Mucilage plays crucial roles in root-soil interactions. Collection systems for maize (Zea mays L.) use primary and seminal roots of aeroponically-grown seedlings (CSA), or brace roots of soil-grown plants (CSB). While each method represents specific plant developmental stages, and root types growing in specific (micro-)environments, these factors are rarely considered. It is unclear whether mucilage exhibits distinct physico-chemical properties related to collection system-inherent factors. Methods Mucilage of maize genotype B73 was collected from systems CSA and CSB. Chemical composition was assessed by pH, nutrient contents, neutral sugar composition, and polysaccharide polymer length. Viscosity, surface tension and contact angle represented physical properties. Results The share of hexoses among total polysaccharides was 11% higher in CSB than in CSA, whereas pentoses were predominant in CSA, together with higher nutrient concentrations and pH values. Mannose was detected only in CSB, which also exhibited higher surface tension, viscosity and contact angle compared to CSA. Conclusions Physico-chemical differences between the two mucilages are related to root type functions, environmental root growth conditions, and plant developmental state. Higher fractions of pentoses in CSA mucilage seem related to semi-sterile system conditions. Higher viscosity of CSB mucilage might reflect the need for enhanced water holding capacity of brace roots growing in drier conditions. A strong influence of environmental factors on mucilage properties even for a single genotype might play additional roles e.g. in the attraction of microbiomes. These aspects are relevant when assessing the role of mucilage in the rhizosphere, or when developing models of rhizosphere processes.

Published
2022

4. DOP80 Integrated tissue transcriptomic and serum proteomic interrogation reveals biomarkers for endoscopic improvement and histologic remission after JAK3/TEC inhibition in Ulcerative Colitis (UC) (Phase 2b Vibrato study)

Author

Hassan-Zahraee PhD, M, primary, Ye, Z, additional, Xi, L, additional, Banerjee, A, additional, He, W, additional, Dushin, E, additional, Lee, J, additional, Altintas, E, additional, Romatowski, J, additional, Leszczyszyn, J, additional, Danese, S, additional, Sandborn, W J, additional, Banfield, C, additional, Gale, J, additional, Peeva, E, additional, Vincent, M, additional, Hyde, C, additional, Longman, R, additional, and Hung, K E, additional

Published
2022
Full Text
View/download PDF

8. A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results

Author

King, B, Guttman-Yassky, E, Peeva, E, Banerjee, A, Sinclair, R, Pavel, AB, Zhu, L, Cox, LA, Craiglow, B, Chen, L, Banfield, C, Page, K, Zhang, W, Vincent, MS, King, B, Guttman-Yassky, E, Peeva, E, Banerjee, A, Sinclair, R, Pavel, AB, Zhu, L, Cox, LA, Craiglow, B, Chen, L, Banfield, C, Page, K, Zhang, W, and Vincent, MS

Abstract

BACKGROUND: Alopecia areata (AA) is an autoimmune form of hair loss with limited treatments. OBJECTIVE: To evaluate the efficacy and safety of the Janus kinase inhibitors ritlecitinib and brepocitinib in patients who have AA with ≥ 50% scalp hair loss. METHODS: Patients were randomized to once-daily ritlecitinib, brepocitinib, or placebo. The primary efficacy endpoint was a 24-week change from baseline in the Severity of Alopecia Tool (SALT) score. The key secondary efficacy endpoint was the proportion of patients achieving 30% improvement in SALT score (SALT30). RESULTS: The ritlecitinib, brepocitinib, and placebo groups included 48, 47, and 47 patients, respectively. At week 24, least-squares mean difference from placebo in SALT score change from baseline was 31.1 (95% confidence interval [CI], 18.8-43.5) for ritlecitinib and 49.2 (95% CI, 36.6-61.7) for brepocitinib (P < .0001 for both comparisons with placebo). SALT30 was achieved by 50% (90% CI, 38%-62%) of patients receiving ritlecitinib, 64% (90% CI, 51%-75%) receiving brepocitinib, and 2% (90% CI, 0%-9%) receiving placebo. Two patients experienced a serious adverse event (rhabdomyolysis) in the brepocitinib group only. LIMITATIONS: Only a single-dosage regimen of each study drug was included. CONCLUSION: Treatment with ritlecitinib or brepocitinib for 24 weeks was efficacious and generally well tolerated.

Published
2021

10. Frontal fibrosing alopecia: a descriptive cross-sectional study of 711 cases in female patients from the UK

Author

McSweeney, SM, Christou, EAA, Dand, N, Boalch, A, Holmes, S, Harries, M, Palamaras, I, Cunningham, F, Parkins, G, Kaur, M, Farrant, P, McDonagh, A, Messenger, A, Jones, J, Jolliffe, V, Ali, I, Ardern-Jones, M, Mitchell, C, Burrows, N, Atkar, R, Banfield, C, Alexandroff, A, Champagne, C, Cooper, HL, Patel, GK, Macbeth, A, Page, M, Bryden, A, Mowbray, M, Wahie, S, Armstrong, K, Cooke, N, Goodfield, M, Man, I, de Berker, D, Dunnil, G, Takwale, A, Rao, A, Siah, T-W, Sinclair, R, Wade, MS, Bhargava, K, Fenton, DA, McGrath, JA, Tziotzios, C, McSweeney, SM, Christou, EAA, Dand, N, Boalch, A, Holmes, S, Harries, M, Palamaras, I, Cunningham, F, Parkins, G, Kaur, M, Farrant, P, McDonagh, A, Messenger, A, Jones, J, Jolliffe, V, Ali, I, Ardern-Jones, M, Mitchell, C, Burrows, N, Atkar, R, Banfield, C, Alexandroff, A, Champagne, C, Cooper, HL, Patel, GK, Macbeth, A, Page, M, Bryden, A, Mowbray, M, Wahie, S, Armstrong, K, Cooke, N, Goodfield, M, Man, I, de Berker, D, Dunnil, G, Takwale, A, Rao, A, Siah, T-W, Sinclair, R, Wade, MS, Bhargava, K, Fenton, DA, McGrath, JA, and Tziotzios, C

Published
2020

11. A phase I, randomized, double‐blind study to assess the safety, tolerability and efficacy of the topical RORC2 inverse agonist PF‐06763809 in participants with mild‐to‐moderate plaque psoriasis

Author

Berstein, G., primary, Zhang, Y., additional, Berger, Z., additional, Kieras, E., additional, Li, G., additional, Samuel, A., additional, Yeoh, T., additional, Dowty, H., additional, Beaumont, K., additional, Wigger‐Alberti, W., additional, von Mackensen, Y., additional, Kroencke, U., additional, Hamscho, R., additional, Garcet, S., additional, Krueger, J. G., additional, Banfield, C., additional, and Oemar, B., additional

Published
2020
Full Text
View/download PDF

12. Frontal fibrosing alopecia: a descriptive cross‐sectional study of 711 cases in female patients from the UK

Author

McSweeney, S.M., primary, Christou, E.A.A., additional, Dand, N., additional, Boalch, A., additional, Holmes, S., additional, Harries, M., additional, Palamaras, I., additional, Cunningham, F., additional, Parkins, G., additional, Kaur, M., additional, Farrant, P., additional, McDonagh, A., additional, Messenger, A., additional, Jones, J., additional, Jolliffe, V., additional, Ali, I., additional, Ardern‐Jones, M., additional, Mitchell, C., additional, Burrows, N., additional, Atkar, R., additional, Banfield, C., additional, Alexandroff, A., additional, Champagne, C., additional, Cooper, H.L., additional, Patel, G.K., additional, Macbeth, A., additional, Page, M., additional, Bryden, A., additional, Mowbray, M., additional, Wahie, S., additional, Armstrong, K., additional, Cooke, N., additional, Goodfield, M., additional, Man, I., additional, Berker, D., additional, Dunnil, G., additional, Takwale, A., additional, Rao, A., additional, Siah, T.‐W., additional, Sinclair, R., additional, Wade, M.S., additional, Bhargava, K., additional, Fenton, D.A., additional, McGrath, J.A., additional, and Tziotzios, C., additional

Published
2020
Full Text
View/download PDF

13. DOP72 Safety, tolerability and efficacy of anti-TL1A antibody PF-06480605 in treatment of ulcerative colitis: The open-label, multicentre, Phase 2a TUSCANY study

Author

Danese, S, primary, Klopocka, M, additional, Scherl, E J, additional, Romatowski, J, additional, Allegretti, J R, additional, Peeva, E, additional, Vincent, M S, additional, Schoenbeck, U, additional, Xi, L, additional, Ye, Z, additional, Hassan-Zahraee, M, additional, Rath, N, additional, Li, G, additional, Neelakantan, S, additional, Banfield, C, additional, Lepsy, C, additional, Chandra, D, additional, and Hung, K E, additional

Published
2020
Full Text
View/download PDF

15. Genome-wide association study in frontal fibrosing alopecia identifies four susceptibility loci including HLA-B*07:02

Author

Tziotzios, C., Petridis, C., Dand, N., Ainali, C., Saklatvala, J.R., Pullabhatla, V., Onoufriadis, A., Pramanik, R., Baudry, D., Lee, S.H., Wood, K., Liu, L., Seegobin, S., Michelotti, G.A., Lwin, S.M., Christou, E.A.A., Curtis, C.J.., de Rinaldis, E., Saxena, A., Holmes, S., Harries, M., Palamaras, I., Cunningham, F., Parkins, G., Kaur, M., Farrant, P., McDonagh, A., Messenger, A., Jones, J., Jolliffe, V., Ali, I., Ardern-Jones, M., Mitchell, C., Burrows, N., Atkar, R., Banfield, C., Alexandroff, A., Champagne, C., Cooper, H.L., Vano-Galvan, S., Maria Molina-Ruiz, A., Ormaechea Perez, N., Patel, G.K., Macbeth, A., Page, M., Bryden, A., Mowbray, M., Wahie, S., Armstrong, K., Cooke, N., Goodfield, M., Man, I., de Berker, D., Dunnill, G., Takwale, A., Rao, A., Siah, T.-W., Sinclair, R., Wade, M.S., Dlova, N.C., Setterfield, J., Lewis, F., Bhargava, K., Kirkpatrick, N., Estivill, X., Stefanato, C.M., Flohr, C., Spector, T., Watt, F.M., Smith, C.H., Barker, J.N., Fenton, D.A., Simpson, M.A., and McGrath, J.A.

Abstract

Frontal fibrosing alopecia (FFA) is a recently described inflammatory and scarring type of hair loss affecting almost exclusively women. Despite a dramatic recent increase in incidence the aetiopathogenesis of FFA remains unknown. We undertake genome-wide association studies in females from a UK cohort, comprising 844 cases and 3,760 controls, a Spanish cohort of 172 cases and 385 controls, and perform statistical meta-analysis. We observe genome-wide significant association with FFA at four genomic loci: 2p22.2, 6p21.1, 8q24.22 and 15q2.1. Within the 6p21.1 locus, fine-mapping indicates that the association is driven by the HLA-B*07:02 allele. At 2p22.1, we implicate a putative causal missense variant in CYP1B1, encoding the homonymous xenobiotic- and hormone-processing enzyme. Transcriptomic analysis of affected scalp tissue highlights overrepresentation of transcripts encoding components of innate and adaptive immune response pathways. These findings provide insight into disease pathogenesis and characterise FFA as a genetically predisposed immuno-inflammatory disorder driven by HLA-B*07:02.

Published
2019

17. Genome-wide association study in frontal fibrosing alopecia identifies four susceptibility loci including HLA-B*07:02

Author

Tziotzios, C, Petridis, C, Dand, N, Ainali, C, Saklatvala, JR, Pullabhatla, V, Onoufriadis, A, Pramanik, R, Baudry, D, Lee, SH, Wood, K, Liu, L, Seegobin, S, Michelotti, GA, Lwin, SM, Christou, EAA, Curtis, CJ, de Rinaldis, E, Saxena, A, Holmes, S, Harries, M, Palamaras, I, Cunningham, F, Parkins, G, Kaur, M, Farrant, P, McDonagh, A, Messenger, A, Jones, J, Jolliffe, V, Ali, I, Ardern-Jones, M, Mitchell, C, Burrows, N, Atkar, R, Banfield, C, Alexandroff, A, Champagne, C, Cooper, HL, Vano-Galvan, S, Maria Molina-Ruiz, A, Ormaechea Perez, N, Patel, GK, Macbeth, A, Page, M, Bryden, A, Mowbray, M, Wahie, S, Armstrong, K, Cooke, N, Goodfield, M, Man, I, de Berker, D, Dunnill, G, Takwale, A, Rao, A, Siah, T-W, Sinclair, R, Wade, MS, Dlova, NC, Setterfield, J, Lewis, F, Bhargava, K, Kirkpatrick, N, Estivill, X, Stefanato, CM, Flohr, C, Spector, T, Watt, FM, Smith, CH, Barker, JN, Fenton, DA, Simpson, MA, McGrath, JA, Tziotzios, C, Petridis, C, Dand, N, Ainali, C, Saklatvala, JR, Pullabhatla, V, Onoufriadis, A, Pramanik, R, Baudry, D, Lee, SH, Wood, K, Liu, L, Seegobin, S, Michelotti, GA, Lwin, SM, Christou, EAA, Curtis, CJ, de Rinaldis, E, Saxena, A, Holmes, S, Harries, M, Palamaras, I, Cunningham, F, Parkins, G, Kaur, M, Farrant, P, McDonagh, A, Messenger, A, Jones, J, Jolliffe, V, Ali, I, Ardern-Jones, M, Mitchell, C, Burrows, N, Atkar, R, Banfield, C, Alexandroff, A, Champagne, C, Cooper, HL, Vano-Galvan, S, Maria Molina-Ruiz, A, Ormaechea Perez, N, Patel, GK, Macbeth, A, Page, M, Bryden, A, Mowbray, M, Wahie, S, Armstrong, K, Cooke, N, Goodfield, M, Man, I, de Berker, D, Dunnill, G, Takwale, A, Rao, A, Siah, T-W, Sinclair, R, Wade, MS, Dlova, NC, Setterfield, J, Lewis, F, Bhargava, K, Kirkpatrick, N, Estivill, X, Stefanato, CM, Flohr, C, Spector, T, Watt, FM, Smith, CH, Barker, JN, Fenton, DA, Simpson, MA, and McGrath, JA

Abstract

Frontal fibrosing alopecia (FFA) is a recently described inflammatory and scarring type of hair loss affecting almost exclusively women. Despite a dramatic recent increase in incidence the aetiopathogenesis of FFA remains unknown. We undertake genome-wide association studies in females from a UK cohort, comprising 844 cases and 3,760 controls, a Spanish cohort of 172 cases and 385 controls, and perform statistical meta-analysis. We observe genome-wide significant association with FFA at four genomic loci: 2p22.2, 6p21.1, 8q24.22 and 15q2.1. Within the 6p21.1 locus, fine-mapping indicates that the association is driven by the HLA-B*07:02 allele. At 2p22.1, we implicate a putative causal missense variant in CYP1B1, encoding the homonymous xenobiotic- and hormone-processing enzyme. Transcriptomic analysis of affected scalp tissue highlights overrepresentation of transcripts encoding components of innate and adaptive immune response pathways. These findings provide insight into disease pathogenesis and characterise FFA as a genetically predisposed immuno-inflammatory disorder driven by HLA-B*07:02.

Published
2019

25. 544 Alopecia areata lesions show significant changes in immune and keratin biomarkers that correlate with clinical improvement with oral Janus kinase inhibitors PF-06651600 (JAK3) and PF-06700841 (TYK2/JAK1)

Author

Guttman-Yassky, E., primary, Pavel, A.B., additional, Page, K., additional, Diaz, A., additional, Banerjee, A., additional, King, B., additional, Zhang, W., additional, Zhu, L., additional, Banfield, C., additional, Cox, L.A., additional, Vincent, M., additional, Dowty, M., additional, and Peeva, E., additional

Published
2019
Full Text
View/download PDF

41. A phase I, randomized, double‐blind study to assess the safety, tolerability and efficacy of the topical RORC2 inverse agonist PF‐06763809 in participants with mild‐to‐moderate plaque psoriasis.

Author

Berstein, G., Zhang, Y., Berger, Z., Kieras, E., Li, G., Samuel, A., Yeoh, T., Dowty, H., Beaumont, K., Wigger‐Alberti, W., Mackensen, Y., Kroencke, U., Hamscho, R., Garcet, S., Krueger, J. G., Banfield, C., and Oemar, B.

Subjects
PSORIASIS, BIOMARKERS, SYMPTOMS, SKIN biopsy, TRANSCRIPTION factors, GINGIVITIS, TOOTHBRUSHES
Abstract

Summary: Background: Transcription factor retinoic acid‐related orphan receptor 2 (RORC2/RORγT) mediates interleukin (IL)‐17A and IL‐17F expression. IL‐17A plays a central role in the pathogenesis of several inflammatory disorders, including psoriasis. The RORC2 inhibitor PF‐06763809 has been hypothesized to inhibit IL‐17A production in T‐helper 17 (Th17) cells, thereby reducing psoriasis symptoms. Aim: To assess the safety, tolerability and effect on skin infiltrate thickness of PF‐06763809 in participants with mild/moderate chronic plaque psoriasis. Methods: This was a randomized, double‐blind, first‐in‐human study (trial registration: ClinicalTrials.gov NCT03469336). Participants received each of the following six treatments once daily for 18 days: three topical doses (2.3%, 0.8%, 0.23%) of PF‐06763809, a vehicle and two active comparators (betamethasone and calcipotriol). Primary endpoints included change from baseline in psoriatic skin infiltrate thickness [echo‐poor band (EPB) on ultrasonography] at Day 19, and safety. Change in psoriasis‐associated gene expression (Day 19), evaluated by real‐time reverse transcription PCR of skin biopsies, was an exploratory endpoint. Results: In total, 17 participants completed the study. Change from baseline in the EPB on Day 19 for all three doses of PF‐06763809 was not significantly different from that of vehicle (P > 0.05). A significant reduction in EPB from baseline was observed with betamethasone on Day 19 relative to all other treatments (P < 0.0001). Treatment‐related adverse events were mild/moderate. There were no significant differences in gene expression on Day 19 between vehicle and PF‐06763809‐treated skin lesions. Conclusion: Using a psoriasis plaque test design, PF‐06763809 was found to be well tolerated with an acceptable safety profile in participants with psoriasis, but without reduction in skin infiltrate thickness or disease biomarkers. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

43. Efficacy and safety of the Janus kinase 1 inhibitor PF-04965842 in patients with moderate-to-severe psoriasis: phase II, randomized, double-blind, placebo-controlled study

Author

Schmieder, G.J., primary, Draelos, Z.D., additional, Pariser, D.M., additional, Banfield, C., additional, Cox, L., additional, Hodge, M., additional, Kieras, E., additional, Parsons-Rich, D., additional, Menon, S., additional, Salganik, M., additional, Page, K., additional, and Peeva, E., additional

Published
2018
Full Text
View/download PDF

44. Pharmacokinetic interaction studies between felbamate and vigabatrin

Author

Affrime, M. B., Banfield, C., Colucci, R., Paul Glue, Guillaume, M., Lim, J., Lin, C., Meehan, J., Nomeir, A., Radwanski, E., Reidenberg, P., and Rey, E.

Subjects
Adult, Male, genetic structures, medicine.medical_treatment, Phenylcarbamates, Administration, Oral, Pharmacology, Placebo, Vigabatrin, Gas Chromatography-Mass Spectrometry, Felbamate, Pharmacokinetics, Short Reports, Double-Blind Method, Oral administration, medicine, Humans, Pharmacology (medical), Drug Interactions, gamma-Aminobutyric Acid, Analysis of Variance, Cross-Over Studies, Chemistry, Stereoisomerism, Drug interaction, Crossover study, Anticonvulsant, Propylene Glycols, Anticonvulsants, medicine.drug
Abstract

To assess the possible occurrence of pharmacokinetic interactions between the antiepileptic agents felbamate and vigabatrin, two randomized, double-blind, placebo-controlled, crossover studies were conducted in healthy male volunteers. In Study I, 18 subjects received oral vigabatrin 1000 mg every 12 h for two 8 day periods with felbamate 1200 mg every 12 h or placebo. In Study II, 18 other volunteers were administered oral felbamate 1200 mg every 12 h for two 8 day periods with vigabatrin 1000 mg every 12 h or placebo. On the eighth day of each treatment period, blood and urine samples were collected over 12 h for determination of the active S(+)- and inactive R(-)-vigabatrin enantiomer concentrations (Study I) or felbamate concentrations (Study II). In Study I, the pharmacokinetic parameters of R(-)-vigabatrin were similar during co-administration with felbamate or placebo. Felbamate produced a 13% increase in AUC(0,12 h) and an 8% increase in urinary excretion of S(+)-vigabatrin. Although these changes were statistically significant, their magnitude was small. In Study II, the pharmacokinetic parameters of felbamate were similar during concurrent administration with vigabatrin or placebo. These data indicate that there are no clinically relevant pharmacokinetic interactions between felbamate and vigabatrin in man

Published
1995

Catalog

Books, media, physical & digital resources
See catalog results